KERLEDEX
LOE ApproachingNDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLEDEX is an oral tablet small-molecule NDA approved by Sanofi in October 1992. The mechanism of action and specific indications are not publicly disclosed in available data. The product is approaching loss of exclusivity (LOE), indicating it has been on market for over three decades.
LOE Approaching
Product faces moderate competitive pressure (score: 30/100) with LOE imminent, signaling potential team consolidation or transition planning at Sanofi.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KERLEDEX currently has zero linked job openings, reflecting its mature, stable market position and approaching LOE. Career growth on this product is limited; opportunities exist mainly in managed-decline strategies, pricing defense, or transition to newer portfolio assets at Sanofi.
Brand ManagerField Sales Representative
Worked on KERLEDEX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.